{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Beta+Thalassemia-Major&page=3",
    "query": {
      "condition": "Beta Thalassemia-Major",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Beta+Thalassemia-Major&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Beta+Thalassemia-Major&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T08:58:36.691Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006136",
      "title": "Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "arginine butyrate",
          "type": "DRUG"
        },
        {
          "name": "epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "1999-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-11-08",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 6,
      "location_summary": "Oakland, California • New Haven, Connecticut • Bethesda, Maryland + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006136"
    },
    {
      "nct_id": "NCT01241357",
      "title": "High-Tc Susceptometer to Monitor Transfusional Iron Overload",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transfusional Iron Overload",
        "Thalassemia Major",
        "Sickle Cell Disease",
        "Myelodysplastic Syndromes",
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Hepatic biomagnetic susceptibility measurement",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "5 Years to 80 Years"
      },
      "enrollment_count": 99,
      "start_date": "2011-03",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-09-21",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01241357"
    },
    {
      "nct_id": "NCT02675959",
      "title": "Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Defibrotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-07-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675959"
    },
    {
      "nct_id": "NCT06664541",
      "title": "Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Transfusion Dependent Beta Thalassemia",
        "Sickle Cell Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-10-01",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06664541"
    },
    {
      "nct_id": "NCT00061763",
      "title": "Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta-thalassemia",
        "Myelodysplastic Syndromes",
        "Fanconi Syndrome",
        "Anemia, Diamond-Blackfan",
        "Anemia, Aplastic"
      ],
      "interventions": [
        {
          "name": "Deferasirox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2003-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-08-22",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 6,
      "location_summary": "Oakland, California • Stanford, California • Arlington Heights, Illinois + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061763"
    },
    {
      "nct_id": "NCT00004412",
      "title": "Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Skin Ulcers",
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "Arginine Butyrate",
          "type": "DRUG"
        },
        {
          "name": "Standard local care dressing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Susan P. Perrine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 23,
      "start_date": "1997-09",
      "completion_date": "2005-02",
      "has_results": true,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004412"
    },
    {
      "nct_id": "NCT01709032",
      "title": "Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Thalassemia Major With Severe Transfusional Iron Overload"
      ],
      "interventions": [
        {
          "name": "Deferasirox and deferiprone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-09",
      "completion_date": "2017-08-01",
      "has_results": true,
      "last_update_posted_date": "2019-03-06",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709032"
    },
    {
      "nct_id": "NCT00115349",
      "title": "Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Heart Diseases",
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Deferoxamine",
          "type": "DRUG"
        },
        {
          "name": "Deferiprone (L1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carelon Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 20,
      "start_date": "2005-06",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00115349"
    },
    {
      "nct_id": "NCT02326597",
      "title": "Decision Aid for Therapeutic Options In Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia",
        "Hemoglobin SS",
        "Hemoglobin SC",
        "Hemoglobin Beta Thalassemia"
      ],
      "interventions": [
        {
          "name": "Decision Aid Tool",
          "type": "OTHER"
        },
        {
          "name": "Standard Practice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "8 Years to 80 Years"
      },
      "enrollment_count": 134,
      "start_date": "2015-01",
      "completion_date": "2017-04-17",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326597"
    },
    {
      "nct_id": "NCT02179359",
      "title": "Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Transfusion Dependent Alpha- or Beta- Thalassemia",
        "Diamond Blackfan Anemia",
        "Paroxysmal Nocturnal Hemoglobinuria",
        "Glanzmann Thrombasthenia",
        "Severe Congenital Neutropenia",
        "Shwachman-Diamond Syndrome",
        "Non-Malignant Hematologic Disorders"
      ],
      "interventions": [
        {
          "name": "Reduced Toxicity Ablative Regimen",
          "type": "DRUG"
        },
        {
          "name": "Reduced Intensity Preparative Regimen",
          "type": "DRUG"
        },
        {
          "name": "Myeloablative Preparative Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2014-09-02",
      "completion_date": "2024-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-10-06T08:58:36.691Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02179359"
    }
  ]
}